Workshops & Webinars 2024
Our exciting initiative continues!
Our Experts to Experts Program aims to intensify the dialogue between you and our experts through on-site workshops and webinars. This program offers a continuous exchange of knowledge for the entire Zytomed Systems product portfolio. Explore your options.
You can request the program including a series of scientific activities for the upcoming months at workshop@zytomed-systems.de or webinar@zytomed-systems.de.
If you need further information or have any questions, please do not hesitate to contact us.
We are delighted to inform you that due to the positive customer response, the molecular diagnostic products of our partner AmoyDx® are now available to our customers in Switzerland through ZytoMax Schweiz GmbH, a sister company of Zytomed Systems GmbH.
A recently conducted study has shown that TRPS1 is expressed very highly in triple-negative breast cancer (TNBC). Expression was significantly higher than the GATA3 expression in metaplastic (85% vs. 21%) and non-metaplastic (86% vs. 51%) TNBC. Accordingly, TRPS1 has proven to be a highly specific and sensitive marker for all types of breast cancer, in particular TNBC. (Di Ai et al.; "TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Mod Pathol 34: 710-719, 2021)